Seaport Therapeutics (NASDAQ:SPTX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 142.13% from the company’s current price.
Several other equities research analysts also recently weighed in on the company. Seaport Research Partners set a $50.00 price target on Seaport Therapeutics in a report on Wednesday, July 15th. Zacks Research raised shares of Seaport Therapeutics to a “hold” rating in a report on Wednesday, May 27th. UBS Group lowered shares of Seaport Therapeutics to a “sell” rating in a research note on Tuesday, June 9th. Wolfe Research initiated coverage on shares of Seaport Therapeutics in a report on Tuesday, July 7th. They set a “hold” rating for the company. Finally, Citigroup started coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $38.40.
Get Our Latest Analysis on Seaport Therapeutics
Seaport Therapeutics Stock Up 0.9%
Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($1.07).
Insider Buying and Selling
In related news, Director Robert J. Hombach bought 13,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at approximately $235,820. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry.
Read More
- Five stocks we like better than Seaport Therapeutics
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
